Open AccessA Review on Mucormycosis with recent pharmacological treatment
Author(s) -
Yogita B. Shinde,
Sanket Kore
Publication year - 2021
Publication title -
journal of drug delivery and therapeutics
Language(s) - English
Resource type - Journals
ISSN - 2250-1177
DOI - 10.22270/jddt.v11i3-s.4844
Subject(s) - mucormycosis , amphotericin b , antifungal , mucorales , medicine , refractory (planetary science) , intensive care medicine , antifungal drugs , surgery , dermatology , biology , astrobiology
Mucormycosis is antifungal eye infection difficult to manage this infection with limited use of diagnostic tool and therapeutic option, but previous literature studied diagnostic strategies and evaluate the potency of antifungal agent as a treatment option. Mucormycosis was difficult to study on imaging studies. Surgery plus antifungal therapy of high dose yields greater survival rates. Mucorales are most widely resisted to the used as an antifungal agent. Amphotericin -B were kept for de-escalation refractory therapy whereas, patient’s intolerant to Amphotericin B.
Keywords: Mucormycosis, amphotericin, antifungal agents